[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 315,223,616
  • Shares Outstanding, K 2,469,824
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 12,969 M
  • EBITDA $ 18,807 M
  • 60-Month Beta 0.19
  • Price/Sales 4.70
  • Price/Cash Flow 10.57
  • Price/Book 6.49

Options Overview Details

View History
  • Implied Volatility 34.04% (+1.35%)
  • Historical Volatility 33.75%
  • IV Percentile 94%
  • IV Rank 89.96%
  • IV High 35.42% on 04/27/26
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 7) 1.15 (0.88%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 5,821
  • Volume Avg (30-Day) 19,634
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 461,305
  • Open Int (30-Day) 433,225
  • Expected Range 129.40 to 131.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.21
  • Number of Estimates 3
  • High Estimate $-0.20
  • Low Estimate $-0.22
  • Prior Year $2.13
  • Growth Rate Est. (year over year) -109.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.57 +17.46%
on 06/18/26
131.56 -0.39%
on 07/17/26
+15.80 (+13.52%)
since 06/17/26
3-Month
107.90 +21.46%
on 04/29/26
131.56 -0.39%
on 07/17/26
+12.17 (+10.06%)
since 04/17/26
52-Week
76.66 +70.95%
on 07/29/25
131.56 -0.39%
on 07/17/26
+49.72 (+60.76%)
since 07/17/25

Most Recent Stories

More News
Stocks Settle Lower as Chipmakers and AI Stocks Slump

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.51%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.62%. September...

MSTR : 92.94 (-1.16%)
GOOGL : 345.29 (-2.59%)
SNDK : 1,440.47 (+2.08%)
HL : 14.38 (-0.96%)
CDE : 14.46 (-2.23%)
GLXY : 21.71 (-2.69%)
FDXF : 155.95 (+2.31%)
COIN : 157.93 (-1.60%)
CRWV : 72.65 (-0.36%)
STX : 742.19 (-0.44%)
WDC : 458.59 (-1.76%)
AMD : 489.47 (-2.29%)
Stocks Mixed as Weakness in Chipmakers Weighs

The S&P 500 Index ($SPX ) (SPY ) today is down -0.14%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.96%. September E-mini S&P futures...

MSTR : 92.94 (-1.16%)
SNDK : 1,440.47 (+2.08%)
HL : 14.38 (-0.96%)
CDE : 14.46 (-2.23%)
GLXY : 21.71 (-2.69%)
FDXF : 155.95 (+2.31%)
COIN : 157.93 (-1.60%)
STX : 742.19 (-0.44%)
WDC : 458.59 (-1.76%)
AMD : 489.47 (-2.29%)
UPS : 117.29 (+0.09%)
SCCO : 174.74 (-0.52%)
Stocks Pressured by a Renewed Selloff in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is down -0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.28%. September E-mini S&P futures...

MSTR : 92.94 (-1.16%)
SAIA : 431.86 (-1.47%)
UAL : 117.50 (-1.10%)
AVGO : 371.07 (-0.90%)
SNDK : 1,440.47 (+2.08%)
GLXY : 21.71 (-2.69%)
MRK : 130.68 (+2.39%)
TXN : 285.61 (-1.93%)
FDXF : 155.95 (+2.31%)
$IUXX : 28,616.27 (-1.41%)
COIN : 157.93 (-1.60%)
ARCB : 160.03 (+1.54%)
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a placebo-adjusted 56% and 59%, respectively LIPFENDRA is a novel...

MRK : 130.68 (+2.39%)
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

Late-breaker presentations will highlight investigational, once-weekly oral combinations of islatravir with lenacapavir (Phase 3 ISL/LEN) and with ulonivirine (Phase 2b ISL+ULO) in adults with virologically-suppressed...

MRK : 130.68 (+2.39%)
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

KEYTRUDA is the first and only PD-1 inhibitor to improve PFS compared to platinum doublet chemotherapy for these patients in a Phase 3 trial

MRK : 130.68 (+2.39%)
Earnings Preview: What To Expect From Merck & Co.'s Report

Merck & Co. is expected to announce its second-quarter earnings in August, and Wall Street forecasts a double-digit decline in its profits.

XLV : 162.65 (+0.53%)
$SPX : 7,485.90 (-0.64%)
MRK : 130.68 (+2.39%)
TERN : 52.95 (+0.04%)
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

First and only PD-1 inhibitor plus antibody-drug conjugate regimens approved for patients with MIBC regardless of cisplatin eligibility Approvals based on Phase 3 KEYNOTE-B15...

MRK : 130.68 (+2.39%)
This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026

Merck & Co. has outperformed the S&P 500 in 2026, rising 19% year-to-date while offering a 2.61% dividend yield supported by 15 consecutive years of dividend increases.

GOOG : 344.61 (-2.60%)
GOOGL : 345.29 (-2.59%)
$SPX : 7,485.90 (-0.64%)
MRK : 130.68 (+2.39%)
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on...

MRK : 130.68 (+2.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 134.64
2nd Resistance Point 131.78
1st Resistance Point 129.71
Last Price 130.68
1st Support Level 124.78
2nd Support Level 121.92
3rd Support Level 119.85

See More

52-Week High 131.56
Last Price 130.68
Fibonacci 61.8% 110.60
Fibonacci 50% 104.12
Fibonacci 38.2% 97.64
52-Week Low 76.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.